Articles

Emerging markets give Lilly hope in patent crunch

In a kind of alternate drug universe, sales of Eli Lilly and Co.’s ghosts of blockbusters past are soaring in China—prompting the drugmaker to pour money into emerging markets in an attempt to prop up revenue.

Read More

Lilly’s master plan for downtown (real estate)

As Eli Lilly and Co. outsources work and sheds unnecessary properties, it is making moves with surplus real estate that could establish the strongest physical connection between Lilly and downtown since the company was founded at Pearl and Meridian streets 135 years ago.

Read More

Q&A

Harlon Wilson, president of Indianapolis-based Medical Animatics, says the uncertainty created by the recession and now health care reform have dried up most opportunities for his 3-D animation firm to win new business with health care clients. So he’s looking at new markets—such as the recent online learning work for Harrison College that led Medical Animatics to sell some of its assets to the for-profit university. And Wilson is still banking on persistent needs to educate patients to cause health care to bounce back.

Read More

Fort Wayne firm to open health info to patients

With electronic medical record systems proliferating, there’s information galore about patients. But it’s not so easy for patients to get at it. Now Fort Wayne-based NoMoreClipboard has been charged to design ways to fix that problem.

Read More

Diabetes boom sparks Roche expansion

Roche Diagnostics Corp. is expanding one of its Indianapolis manufacturing plants to keep up with growing sales of its leading brand of blood glucose monitors.

Read More

Health insurers expect hit from reform rule

Major health insurers, including WellPoint, say a provision that requires them to spend a certain percentage of the premiums they collect on care-related costs will eat into earnings this year.

Read More

Recent successes don’t change Lilly’s outlook

Eli Lilly and Co. can be credited with using acquisitions to unclog its product pipeline. It launched two drugs in the past 18 months, won market approval for a third and will likely get nods for two more drugs this year. Trouble is, they all have paltry sales prospects.

Read More